RxDoctor Payments Data

Christopher Nickison, MD

Internal Medicine · Lancaster, OHNPI 1962481465

Payments from drug & device makers

$1,508in general payments, 2019–2025

Across 85 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Pfizer$186
  • Abbott$156
  • Novo Nordisk$132
  • Johnson & Johnson$125
  • Otsuka America Pharmaceutical, Inc.$99
  • plus $426 from 13 others

What the payments were for

  • Food & beverage$1,508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,508 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$93,734
Medicare patients
291
Services billed
2,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$108,277
OzempicSemaglutide62$59,633
XareltoRivaroxaban38$46,762
MytesiCrofelemer11$28,387
JanuviaSitagliptin Phosphate28$26,857
JardianceEmpagliflozin30$17,673
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$15,518
MounjaroTirzepatide11$14,103
Omeprazole536$6,495
SynthroidLevothyroxine Sodium80$5,704
Losartan Potassium410$5,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,185
Advair HfaFluticasone Propion/Salmeterol15$5,089
Metoprolol Succinate226$4,903
Levothyroxine Sodium568$4,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$108,277105 claims
Novo NordiskOzempic$132$59,63362 claims
Johnson & JohnsonXarelto$125$46,76238 claims
Lilly USA, LLCMounjaro$59$14,10311 claims
AbbVieSynthroid$383$5,70480 claims
GSKArnuity Ellipta$16$4,37621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →